Searched for
CPAAS INDIA MARKET
Apple ties up with Jio to enable 'RCS' messaging service on iPhonesApple has partnered with Reliance Jio to introduce Rich Communication Services (RCS) on iPhones in India, enabling Jio users to exchange iM...- India's business messaging market set to hit billion-dollar revenue mark in 2025India's business messaging market will exceed $1 billion by 2025. Growth will be driven by WhatsApp Business and RCS. Innovations like Appl...
- CPaas is here to stay, says new CEO of Sinch, Laurinda Y PangMobile phone companies in India have failed to eliminate the need for cloud-based communication services despite offering messaging and cal...
- Proximus sets ambitious targets after acquisition of Route Mobile in India's largest inbound FDI dealRajdip Gupta, managing director and chief executive of RML, who will now lead the Proximus group’s global CPaaS business said, he finds imm...
- Proximus thinks the route is clear for a 15% margin boostProximus targets revenue growth by acquiring Route Mobile, expanding globally with generative AI. Telesign's fraud solution introduced in I...
- Google-backed RCS isn’t a threat to WhatsApp Business, says Meta executiveMeta executive Tarcisio Ribiero’s comments come at a time when a battle is brewing between tech giant Google and Meta's WhatsApp over the r...
- AI will eat up some jobs but also create many new opportunities: InfobipEfficient automation will create more employment opportunities than ever in the communication space, says Ivan Ostojic of Infobip. He expla...
- Airtel exploring offering CPAAS platform in overseas marketsBharti Airtel is considering offering its communication as a service platform outside India, aiming to capitalise on the potential of the g...
- Proximus deal opens up North American market: Route Mobile CEO Rajdip GuptaOn completion of the deal, Route would be able to operate in the high-margin CPaaS market in the US and, in return, Proximus could drive co...
- Tata Communications Q1: Net profit down 30% YoY, revenue up 11%The pressure on profits was led by a higher mix of digital portfolio of services instead of core connectivity solutions, AS Lakshminarayana...
- Tanla Platforms to acquire ValueFirst for Rs 346 crore from TwilioTo this effect, Tanla has signed a definitive share purchase agreement to acquire ValueFirst, “subject to upward closing adjustments in the...
- 3 internet stocks that can rally up to 63%: Yes SecuritiesIndiamart has a dominant market share in B2B classified business with around 65 per cent market share in paid listings. The strength of the...
- Industry tailwinds, deal pipeline to help Route Mobile achieve 40% growth in FY23: CEO"Moving forward, we believe that India will continue to be a major contributor to our overall revenue mix. However, with the acquisition of...
- Buy Tanla Platforms, target price Rs 1867: Yes SecuritiesTanla Platforms Ltd., incorporated in the year 1995, is a Small Cap company (having a market cap of Rs 19417.04 Crore) operating in IT Soft...
- The rise of CPaaS: Can Tanla and Route sustain the valuation spike?Route Mobile is smaller than Tanla Platforms, as can be seen from the revenues generated in Q3 of FY22. Route also has lower margins than T...
- Tanla, Microsoft tie-up on blockchain network for encrypted SMSes, emails for businessesIndia’s commercial traffic is managed by leading CPaaS players such as Tata Communications, Route Mobile, Gupshup, Kalyera and close to 50,...
- Ex-J&J India head led fight against patentCancer Patients Aid Association is ironically headed by a former country head of a multi-national medical products company.
- HC allows CPAA to join Bayer-Cipla caseThe Delhi High Court (HC) has allowed cancer patient group Cancer Patients Aid Association (CPAA) to join the Bayer AG and Cipla case.
- NGO to seek compulsory licensing of cancer drugsHealthcare groups, campaigning for access to medicines, are going all out in their fight against drug patents in India.
- Of patents and pre-grant oppositionsOn January 25 this year, the patent office in Chennai rejected a patent application by pharma MNC Novartis for its anti-cancer drug Glivec ...
Load More
